Please login to the form below

Not currently logged in
Email:
Password:

LCZ696

This page shows the latest LCZ696 news and features for those working in and with pharma, biotech and healthcare.

Novartis' Entresto launched in UK

Novartis' Entresto launched in UK

The results of the PARADIGM-HF study showed that patients treated with LCZ696 were 20% less likely to die from a cardiovascular cause or hospitalisation and were also 16% less likely

Latest news

More from news
Approximately 5 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics